Dataset from A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder

This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).

本研究评估了左旋米那普仑缓释剂（levomilnacipran extended-release，ER）相较于安慰剂，用于重度抑郁症（MDD）患者抑郁症复发预防的有效性、安全性与耐受性。